Nicotine has been shown to speed attentional reorienting in cued target detection tasks, and work in young adults suggest that individuals carrying the apolipoprotein E (APOE) e4 allele might show greater sensitivity to the cognitive effects of nicotine. The APOE e4 allele is associated with increased risk of Alzheimer’s disease (AD), and increased sensitivity to nicotine might reflect early cholinergic differences that relate to an enhanced risk of AD. The aim of this study was to investigate effects of nicotine and APOE on attentional reorienting in mid-age participants. APOE e4 (e4+) were compared to non-APOE e4 (e4–) carriers, and functional magnetic resonance imaging (fMRI) data acquired. Neural data showed that nicotine effects, and the network involved in reorienting, was consistent with studies in young adults. Nicotine improved attentional reorienting at the trend level. Although there were no behavioural effects of genotype, genotype effects were present neurally: e4+ showed decreased extrastriate activation, and enhanced effects of nicotine on reorienting in right middle frontal regions. Drug by genotype interactions were present in hippocampal and anterior cingulate regions. These results are consistent with differential sensitivity to nicotine according to APOE status, possibly reflecting abnormal cholinergic function and accelerated cognitive ageing in mid-age e4+.
AraujoDMLapchakPAMeaneyMJ, et al (1990) Effects of aging on nicotinic and muscarinic autoreceptor function in the rat brain: Relationship to presynaptic cholinergic markers and binding sites. J Neurosci10: 3069–3078.
2.
BabicTMahovicLakusicDSerticJ, et al (2004) ApoE genotyping and response to galanthamine in Alzheimer’s disease–a real life retrospective study. Coll Antropol28: 199–204.
3.
BentleyPDriverJDolanRJ (2011) Cholinergic modulation of cognition: Insights from human pharmacological functional neuroimaging. Prog Neurobiol94: 360–388.
4.
BizzarroAMarraCAcciarriA, et al (2005) Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer’s disease. Dement Geriatr Cogn Disord20: 254–261.
5.
BookheimerSYStrojwasMHCohenMS, et al (2000) Patterns of brain activation in people at risk for Alzheimer’s disease. N Engl J Med343: 450–456.
6.
CabezaRDaselaarSMDolcosF, et al (2004) Task-independent and task-specific age effects on brain activity during working memory, visual attention and episodic retrieval. Cereb Cortex14: 364–375.
7.
ChicaABBartolomeoPValero-CabreA (2011) Dorsal and ventral parietal contributions to spatial orienting in the human brain. J Neurosci31: 8143–8149.
8.
ChuahLYCheeMW (2008) Cholinergic augmentation modulates visual task performance in sleep-deprived young adults. J Neurosci28: 11369–11377.
9.
CorbettaMShulmanGL (2002) Control of goal-directed and stimulus-driven attention in the brain. Nat Rev Neurosci3: 201–215.
10.
CorbettaMKincadeJMShulmanGL (2002) Neural systems for visual orienting and their relationships to spatial working memory. J Cogn Neurosci14: 508–523.
11.
DearyIJWhitemanMCPattieA, et al (2002) Cognitive change and the APOE epsilon 4 allele. Nature418: 932.
12.
DennisNABrowndykeJNStokesJ, et al (2010) Temporal lobe functional activity and connectivity in young adult APOE varepsilon4 carriers. Alzheimers Dement6: 303–311.
13.
DumasJANewhousePA (2011) The cholinergic hypothesis of cognitive aging revisited again: Cholinergic functional compensation. Pharmacol Biochem Behav99: 254–261.
14.
EickhoffSBStephanKEMohlbergH, et al (2005) A new SPM toolbox for combining probabilistic cytoarchitectonic maps and functional imaging data. NeuroImage25: 1325–1335.
15.
EvansSGrayMADowellNG, et al (2013) APOE E4 carriers show prospective memory enhancement under nicotine, and evidence for specialisation within medial BA10. Neuropsychopharmacology38: 655–663.
16.
GibbsRB (2010) Estrogen therapy and cognition: A review of the cholinergic hypothesis. Endocr Rev31: 224–253.
17.
GiessingCThielCMRoslerF, et al (2006) The modulatory effects of nicotine on parietal cortex activity in a cued target detection task depend on cue reliability. Neuroscience137: 853–864.
18.
GreenwoodPMParasuramanR (1994) Attentional disengagement deficit in nondemented elderly over 75 years of age. Aging and Cognition1: 188–202.
19.
HanSDBondiMW (2008) Revision of the apolipoprotein E compensatory mechanism recruitment hypothesis. Alzheimers Dement4: 251–254.
20.
JonesGMSahakianBJLevyR, et al (1992) Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer’s disease. Psychopharmacology108: 485–494.
21.
KimJBasakJMHoltzmanDM (2009) The role of apolipoprotein E in Alzheimer’s disease. Neuron63: 287–303.
22.
KukoljaJThielCMFinkGR (2009) Cholinergic stimulation enhances neural activity associated with encoding but reduces neural activity associated with retrieval in humans. J Neurosci29: 8119–8128.
23.
LamBHollingdrakeEKennedyJL, et al (2009) Cholinesterase inhibitors in Alzheimer’s disease and Lewy body spectrum disorders: The emerging pharmacogenetic story. Hum Genomics4: 91–106.
24.
LawrenceNSRossTJSteinEA (2002) Cognitive mechanisms of nicotine on visual attention. Neuron36: 539–548.
25.
LevinEDRoseJE (1995) Acute and chronic nicotinic interactions with dopamine systems and working memory performance. Ann N Y Acad Sci757: 245–252.
26.
LopezOLJagustWJDulbergC, et al (2003) Risk factors for mild cognitive impairment in the Cardiovascular Health Study Cognition Study: Part 2. Arch Neurol60: 1394–1399.
27.
MaddenDJ (2007) Aging and visual attention. Curr Dir Psychol Sci16: 70–74.
28.
MaldjianJALaurientiPJKraftRABurdetteJH (2003) An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fmri data sets. NeuroImage19: 1233–1239.
29.
MarchantNLKingSLTabetN, et al (2010) Positive effects of cholinergic stimulation favor young APOE epsilon4 carriers. Neuropsychopharmacology35: 1090–1096.
30.
MesulamMM (2004) The cholinergic innervation of the human cerebral cortex. Prog Brain Res145: 67–78.
31.
MesulamMMVolicerLMarquisJK, et al (1986) Systematic regional differences in the cholinergic innervation of the primate cerebral cortex: Distribution of enzyme activities and some behavioral implications. Ann Neurol19: 144–151.
32.
NelsonHEWillisonJ
(1991) National Adult Reading Test (NART): Test manual, 2 edn. NFER Nelson: Windor.
33.
NewhousePKellarKAisenP, et al (2012) Nicotine treatment of mild cognitive impairment: A 6-month double-blind pilot clinical trial. Neurology78: 91–101.
34.
NewhousePAPotterASinghA (2004) Effects of nicotinic stimulation on cognitive performance. Curr Opin Pharmacol4: 36–46.
35.
NewhousePAPotterASDumasJA, et al (2011) Functional brain imaging of nicotinic effects on higher cognitive processes. Biochem Pharmacol82: 943–951.
36.
NordbergAAlafuzoffIWinbladB (1992) Nicotinic and muscarinic subtypes in the human brain: Changes with aging and dementia. J Neurosci Res31: 103–111.
37.
PhillipsJMMcAlonanKRobbWG, et al (2000) Cholinergic neurotransmission influences covert orientation of visuospatial attention in the rat. Psychopharmacology150: 112–116.
38.
RebeckGWReiterJSStricklandDK, et al (1993) Apolipoprotein E in sporadic Alzheimer’s disease: Allelic variation and receptor interactions. Neuron11: 575–580.
39.
ReinvangIWinjevollILRootweltH, et al (2009) Working memory deficits in healthy APOE epsilon 4 carriers. Neuropsychologia48: 566–573.
40.
RustedJKingSLDowellNG, et al (2012) APOE e4 polymorphism in young adults is associated with improved attention and indexed by distinct neural signatures. Neuroimage65: 364–373.
41.
SabbaghMCummingsJ (2011) Progressive cholinergic decline in Alzheimer’s Disease: Consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology. BMC Neurol11: 21.
42.
SarterMGehringWJKozakR (2006) More attention must be paid: The neurobiology of attentional effort. Brain Res Rev51: 145–160.
43.
SchiepersOJHarrisSEGowAJ, et al (2012) APOE E4 status predicts age-related cognitive decline in the ninth decade: Longitudinal follow-up of the Lothian Birth Cohort 1921. Mol Psychiatry17: 315–324.
44.
SchneiderNGLunellEOlmsteadRE, et al (1996) Clinical pharmacokinetics of nasal nicotine delivery. A review and comparison to other nicotine systems. Clin Pharmacokinet31: 65–80.
45.
SmallBJRosnickCBFratiglioniL, et al (2004) Apolipoprotein E and cognitive performance: A meta-analysis. Psychol Aging19: 592–600.
46.
TalesAMuirJLBayerA, et al (2002) Spatial shifts in visual attention in normal ageing and dementia of the Alzheimer type. Neuropsychologia40: 2000–2012.
47.
TanabeJNybergEMartinLF, et al (2011) Nicotine effects on default mode network during resting state. Psychopharmacology216: 287–295.
48.
ThielCMFinkGR (2008) Effects of the cholinergic agonist nicotine on reorienting of visual spatial attention and top-down attentional control. Neuroscience152: 381–390.
49.
ThielCMZillesKFinkGR (2004) Cerebral correlates of alerting, orienting and reorienting of visuospatial attention: an event-related fMRI study. Neuroimage21: 318–328.
50.
ThielCMZillesKFinkGR (2005) Nicotine modulates reorienting of visuospatial attention and neural activity in human parietal cortex. Neuropsychopharmacology30: 810–820.
51.
ThienelRVossBKellermannT, et al (2009) Nicotinic antagonist effects on functional attention networks. Int J Neuropsychopharmacol12: 1295–1305.
52.
TrachtenbergAJFilippiniNCheesemanJ, et al (2012a) The effects of APOE on brain activity do not simply reflect the risk of Alzheimer’s disease. Neurobiol Aging33: 618 e611–618 e613.
53.
TrachtenbergAJFilippiniNEbmeierKP, et al (2012b) The effects of APOE on the functional architecture of the resting brain. NeuroImage59: 565–572.
54.
TuminelloERHanSD (2011) The apolipoprotein e antagonistic pleiotropy hypothesis: Review and recommendations. Int J Alzheimers Dis2011: 726197.
55.
UchidaSHottaH (2009) Cerebral cortical vasodilatation mediated by nicotinic cholinergic receptors: Effects of old age and of chronic nicotine exposure. Biol Pharm Bull32: 341–344.
56.
VosselSThielCMFinkGR (2008) Behavioral and neural effects of nicotine on visuospatial attentional reorienting in non-smoking subjects. Neuropsychopharmacology33: 731–738.
57.
VoytkoML (1996) Cognitive functions of the basal forebrain cholinergic system in monkeys: Memory or attention?Behav Brain Res75: 13–25.
58.
WachterNJGilbertDG (2013) Nicotine differentially modulates antisaccade eye-gaze away from emotional stimuli in nonsmokers stratified by pre-task baseline performance. Psychopharmacology (Berl)225: 561–568.
59.
ZehnderAEBlasiSBerresM, et al (2009) Impact of APOE status on cognitive maintenance in healthy elderly persons. Int J Geriatr Psychiatry24: 132–141.
